logo
US Health Secretary Kennedy's vaccine panel backs preservative-free flu shot

US Health Secretary Kennedy's vaccine panel backs preservative-free flu shot

US Health Secretary Robert Kennedy Jr's vaccine advisory panel has recommended Americans receive seasonal influenza shots that are free from thimerosal.
Thimerosal is only used in multi-dose vials of flu shots in the US during the 2024-25 flu season, despite decades of studies showing no related safety issues.
Fewer than 5 per cent of the flu shots administered were from such vials, according to the US Food and Drug Administration (FDA).
Anti-vaccine groups have linked thimerosal to autism and other neurodevelopmental disorders for decades.
Mr Kennedy wrote a book in 2014 in which he advocated for "the immediate removal of mercury" from vaccines. In recent days, he has posted on X about its alleged dangers.
On its website, the FDA said: "There was no evidence that thimerosal in vaccines was dangerous."
The decision to remove it previously was a precautionary measure to decrease overall exposure to mercury among young infants, it added.
Multi-dose forms of CSL's CSL.AX Afluria and Flucelvax as well as Sanofi's SASY.PA Fluzone use thimerosal as a preservative, according to the FDA's website.
Paris-headquartered Sanofi said it would have sufficient supply of its flu vaccine to support customer preference for this season. CSL said it supplies a very low number of multi-dose vials of flu vaccine in response to demand.
The Centers for Disease Control and Prevention (CDC) staff concluded in a report that evidence did not support an association between thimerosal-containing vaccines and autism or other neurodevelopmental disorders.
The report was briefly published and then removed from the meeting's online document site.
Panel member Dr Robert Malone said the directive to remove the staff report came from Mr Kennedy's office.
The panel, called the Advisory Committee on Immunization Practices (ACIP), voted 5-1 in three separate votes to recommend thimerosal-free shots.
The now seven-person panel was installed by Mr Kennedy earlier this month after he fired all 17 previous ACIP outside experts.
The panel advises the CDC on who should take specific vaccines and related products and when they should be given after FDA approval.
It typically meets three times a year and intends to conduct its next meeting in the third quarter, the centres say.
"The risk from influenza is so much greater than the nonexistent — as far as we know — risk from thimerosal," Dr Cody Meissner, the only panel member who voted against the recommendation, said in explaining his vote.
Lyn Redwood, formerly of the Kennedy-founded anti-vaccine group Children's Health Defense, gave the presentation on thimerosal, arguing that it was a neurotoxin.
Ms Redwood's presentation posted on the CDC's website earlier this week initially included a reference to a study that does not exist.
The report she presented to the committee was significantly shorter, removing a slide that made a reference to that study and another saying she did not have any conflicts of interest.
"With the vote on thimerosal this afternoon, the new committee has turned the ACIP process into a farce," said former CDC vaccine adviser Dr Fiona Havers, who resigned last week over Mr Kennedy's changes to vaccine policy.
She said it is unprecedented to have an outside speaker present and then move immediately to a vote.
Evidence is usually compiled formally by the CDC and reviewed by a work group, Dr Havers said.
She added that CDC experts did not present their data publicly to refute Ms Redwood.
CBS and The New York Times have reported that the agency hired Dr Redwood to work in its vaccine safety office.
On Thursday, the committee voted 5-2 to recommend use of Merck's MRK.N recently approved RSV antibody drug Enflonsia for infants eight months or younger whose mothers did not receive a preventive shot during pregnancy.
ACIP panel member Retsef Levi raised safety concerns about the antibody drug, which were addressed by experts at the FDA and CDC.
He said he would be concerned about giving the product to one of his healthy children and was one of the two votes against the recommendation.
The panel's recommendations need to be adopted by either the CDC director or the Health and Human Services Secretary before becoming final.
There is currently no CDC director.
US President Donald Trump's nominee for the post, Susan Monarez, spoke to a Senate committee yesterday as part of the confirmation process.
ABC/Reuters

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Closing Bell: Healthcare sector gives ASX a booster to rise 0.33pc
Closing Bell: Healthcare sector gives ASX a booster to rise 0.33pc

News.com.au

time12 hours ago

  • News.com.au

Closing Bell: Healthcare sector gives ASX a booster to rise 0.33pc

ASX lifts 0.33pc on healthcare sector strength CSL adds 2.4pc as UBS marks ASX healthcare sector as best EPS pick Chinese manufacturing data contracts, but shows signs of stirring Are healthcare bulls returning? The ASX healthcare sector was the best performing of the ASX's 11 subcategories in trade today, handily outperforming the other sectors with a 1.58% jump. With support from industrials (+1%) and consumer discretionary (+0.98%), that was enough for the ASX 200 to make a convincing gain of 0.33% today, having had a steady run of momentum throughout trade. Regis Healthcare (ASX:REG) added 3.2%, Ramsay Health Care (ASX:RHC) 1.9% and Summerset Group (ASX:SNZ) 1.3%. As for our healthcare giants, CSL (ASX:CSL) gained 2.4%, Pro Medicus (ASX:PME) 2% and Cochlear (ASX:COH) 1.7%. If financial giant UBS is to be believed, this may be the start of a bit of a bullish run for ASX biotech stocks, which have been suffering over the past few months. UBS reckons the ASX healthcare sector is now undervalued, offering the best earnings-per-share growth of all sectors, and forecasting a 20% increase in the 2025-26 year. 'Investor sentiment towards the healthcare sector has broadly cooled over the past year, with some marked deterioration seen across many stocks,' UBS says. 'Cochlear in particular has seen investor apathy build over the last year, which represents a significant change of views.' Back on the ASX today, the main drag was in the materials sector, down 0.77%. The ASX 200 Resources index was also an anchor, shedding 0.96%, but it was outweighed by gains in the All Tech, Gold and Small Ords indices. Chinese manufacturing data contracts again While iron ore has been enjoying a small uptick in pricing the past five days or so, the latest data out of China isn't the best news for Aussie base metal stocks. Manufacturing activity from our largest trading partner fell again for a third month straight in June, despite Beijing's attempts to stimulate the sector. The official purchasing manager's index did improve slightly from 49.5 in May to 49.7 in June, but remained below the 50-point benchmark which indicates whether the index is expanding or contracting. Inventory and employment levels at factories fell as well, but the news wasn't all bad. The sub-index tracking manufacturing production rose to 51 and new orders lifted to 50.2, which could indicate the first stirrings of momentum beginning to build in China's industrial activity. Chinese Premier Li Qiang said Chinese authorities would implement measures to 'make China a mega-sized consumption powerhouse' as well as a manufacturing one in a speech at the World Economic Forum's annual conference in China. 'We still think that there are challenges this year, but I think it's not as far-fetched as we thought before,' Oxford Economics lead economist for China Louise Loo said. 'However punitive tariffs are, I think in the near term, it's quite hard to decouple China from global supply chains, and that means we will continue to see China exports, at least, remain quite competitive, and that should support economic growth for the Chinese.' It remains to be seen if that will translate into higher demand for Australian iron ore, but one can hope. ASX SMALL CAP LEADERS Today's best performing small cap stocks: Security Name Last % Change Volume Market Cap WEL Winchester Energy 0.002 100% 165600 $1,363,019 LSR Lodestar Minerals 0.011 83% 42455380 $1,910,543 ADD Adavale Resource Ltd 0.0015 50% 15489651 $2,287,279 ADY Admiralty Resources. 0.006 50% 1690337 $10,517,918 EEL Enrg Elements Ltd 0.0015 50% 860601 $3,253,779 MPR Mpower Group Limited 0.01 43% 5225088 $2,405,923 GTE Great Western Exp. 0.011 38% 3625782 $4,542,063 MEG Megado Minerals Ltd 0.023 35% 4786016 $10,313,615 ALM Alma Metals Ltd 0.004 33% 2325000 $5,261,182 FCT Firstwave Cloud Tech 0.016 33% 3070713 $20,562,224 FHS Freehill Mining Ltd. 0.004 33% 15028446 $10,241,561 GTR Gti Energy Ltd 0.004 33% 5538733 $8,996,849 SPX Spenda Limited 0.008 33% 16838995 $27,691,293 GLH Global Health Ltd 0.068 33% 176778 $2,987,301 AAU Antilles Gold Ltd 0.005 25% 6046776 $9,516,272 ERL Empire Resources 0.005 25% 692641 $5,935,653 RCM Rapid Critical 0.0025 25% 1125000 $2,831,556 ROG Red Sky Energy. 0.005 25% 120000 $21,688,909 TMX Terrain Minerals 0.0025 25% 5339766 $5,063,629 VR1 Vection Technologies 0.036 24% 40421798 $51,255,235 THR Thor Energy PLC 0.011 22% 2677843 $6,397,109 KNB Koonenberrygold 0.039 22% 46537381 $32,790,159 RPG Raptis Group Limited 0.063 21% 185561 $18,235,612 NGX Ngxlimited 0.145 21% 45773 $10,873,421 SDV Scidev Ltd 0.36 20% 293999 $57,026,459 Making news… Lodestar Minerals (ASX:LSR) is looking to follow up on gold hits at its Chilean copper-gold projects with proceeds from a $2.2m two-tranche share placement. LSR is offering $475k in the first tranche to clients of lead manager Oakley Capital Partners, with the rest hanging on shareholder approval. Adavale Resources (ASX:ADD) is preparing to put drill bit to ground at the London Victoria Mine in NSW, which historically produced gold grades up to 43.8 g/t gold. It's the first exploration at the mine in 30 years; ADD will target shallow extensions to the existing mineral resource estimate, which currently sits at 115,000 ounces of gold. FirstWave Cloud Technology (ASX:FCT) has inked a licensing agreement with Claro Dominican Republic to license its NMIS v9 network management software suite for an upfront fee of US$250k. It's a pure-profit contract, as the contract doesn't require delivery, support or professional services. GTI Energy (ASX:GTR) is locking in a $4.5m placement at an issue price of 0.035 cents a share, a 16.7% premium to the last close price of 0.030 cents. The money will be funnelled directly to resource expansion and infill drilling at the Lo Herma uranium project. GTR's recent scoping study revealed a potential pre-tax net present value of between $174m and $187m and an internal rate of return of between 52% and 66% for Lo Herma. Check out Stockhead's Break it Down for more on GTR's capital raising. Spenda (ASX:SPX) has teamed up with APG Pay Pty Ltd to develop and commercialise a corporate credit platform. The two companies will collab on a scaleable B2B payments space that can scale across multiple industries, starting with the travel industry. Spenda reckons the deal will bring in recurring profit of $1.7m per year. ASX SMALL CAP LAGGARDS Today's worst performing small cap stocks: Security Name Last % Change Volume Market Cap CT1 Constellation Tech 0.001 -50% 1322698 $2,949,467 IS3 I Synergy Group Ltd 0.002 -50% 3892995 $2,002,920 T3D 333D Limited 0.006 -33% 33333 $1,585,651 ADR Adherium Ltd 0.004 -33% 3436600 $5,390,874 TEG Triangle Energy Ltd 0.002 -33% 4164703 $6,267,702 TKL Traka Resources 0.001 -33% 135263 $3,188,685 L1M Lightning Minerals 0.043 -28% 1471249 $6,199,699 ZMM Zimi Ltd 0.008 -27% 616731 $4,702,982 FIN FIN Resources Ltd 0.003 -25% 557800 $2,779,554 GMN Gold Mountain Ltd 0.0015 -25% 1983598 $11,239,518 HLX Helix Resources 0.0015 -25% 1234287 $6,728,387 SFG Seafarms Group Ltd 0.0015 -25% 893383 $9,673,198 SRN Surefire Rescs NL 0.0015 -25% 334051 $4,972,891 TYX Tyranna Res Ltd 0.003 -25% 325000 $13,153,701 GLA Gladiator Resources 0.007 -22% 1626499 $6,824,671 YAR Yari Minerals Ltd 0.012 -20% 2978290 $8,320,672 AUK Aumake Limited 0.002 -20% 1177734 $7,558,397 MEM Memphasys Ltd 0.004 -20% 6329063 $9,917,991 MKL Mighty Kingdom Ltd 0.016 -20% 1737419 $10,326,928 PPG Pro-Pac Packaging 0.016 -20% 78233 $3,633,754 RAN Range International 0.002 -20% 2187661 $2,348,226 SKK Stakk Limited 0.004 -20% 2620995 $10,375,398 VEN Vintage Energy 0.004 -20% 1780465 $10,434,568 HIQ Hitiq Limited 0.014 -18% 1054211 $7,814,865 BDM Burgundy D Mines Ltd 0.029 -17% 604995 $49,746,630 IN CASE YOU MISSED IT QPM Energy (ASX:QPM) is powering up with plans for a new gas-fired plant at the Isaac Energy Hub. Astute Metals (ASX:ASE) has identified four high-priority gold-silver targets at its Needles project in Nevada, USA, thanks to a data review. Green Critical Minerals (ASX:GCM) has cleared another hurdle at the McIntosh graphite project with a PFS showcasing robust economics including $25m post-tax NPV, 25.3% IRR and a 32.5-year mine life. LTR Pharma (ASX:LTP) has completed extractables studies for its Spontan intranasal spray for erectile dysfunction and kicked off a leachables study. Ausgold (ASX:AUC) has released a positive definitive feasibility study for its Katanning gold project (KGP) in WA, highlighting robust returns over a 10-year mine life. Theta Gold Mines' (ASX:TGM) board has rubber stamped the TGME mine in South Africa's Mpumalanga region as high gold prices stir investment in the historic mining district. Break it Down: Anson Resources (ASX:ASN) has paired up with a Korean battery maker to develop a DLE demonstration plant at the Green River project in Utah. Redcastle Resources (ASX:RC1) is on its way to becoming an integrated exploration and production company after lifting resources to 42,000oz at the Redcastle project. TRADING HALTS Australian Mines (ASX:AUZ) – cap raise and potential acquisition AuKing Mining (ASX:AKN) – cap raise Battery Age Minerals (ASX:BM8) – cap raise Blackstone Minerals (ASX:BSX) – cap raise archTIS (ASX:AR9) – cap raise Lodestar Minerals (ASX:LSR) – cap raise Liontown Resources (ASX:LTR) – executive changes Olympio Metals (ASX:OLY) – cap raise Peak Minerals (ASX:PUA) – response to ASX price query Red Mountain Mining (ASX:RMX) – cap raise (ASX:RNT) – cap raise Terra Uranium (ASX:T92) – acquisition and cap raise Vitasora Health (ASX:VHL) – cap raise At Stockhead, we tell it like it is. While GTI Energy is a Stockhead advertiser, it did not sponsor this article.

LTR Pharma completes ED study milestone
LTR Pharma completes ED study milestone

Daily Telegraph

time14 hours ago

  • Daily Telegraph

LTR Pharma completes ED study milestone

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. LTR Pharma & co-development partner Aptar Pharma complete extractables study on SPONTAN All identified compounds below ICH safety thresholds for nasal spray-mist erectile dysfunction treatment Leachables study initiated to support FDA regulatory submission under real-world storage conditions Special Report: LTR Pharma has completed a key extractables study for its SPONTAN intranasal spray for erectile dysfunction and kicked off a leachables study as part of a regulatory development program. LTR Pharma (ASX:LTP) said the extractables study, conducted under the supervision of co-development partner Aptar Pharma, evaluated the bottle and pump components of SPONTAN's container closure system. The study confirmed that all detected compounds were below ICH safety thresholds – the internationally recognised standards adopted by the US Food and Drug Administration (FDA) and regulatory authorities worldwide for pharmaceutical impurities. LTR Pharma said the identified compounds would be monitored in the ongoing leachables study. FDA requires extractables and leachables (E&L) studies for all pharmaceutical products to ensure packaging materials do not compromise product safety or efficacy. For nasal spray products, these studies must meet specific regulatory thresholds due to direct tissue exposure. Leachables study now underway The leachables study has started under Aptar Pharma's management, evaluating the potential migration of the compounds from packaging into SPONTAN under real-world storage conditions. LTR Pharma said SPONTAN used industry-standard bottle and pump components as used in multiple FDA-approved nasal spray products. The study will run for at least 24 months to support shelf-life requirements. Consistent with FDA practice for nasal sprays, the company can submit its application once sufficient robust data is available, with study completion continuing post-approval as standard. E&L studies form part of LTR Pharma's comprehensive regulatory strategy following its FDA pre-IND meeting, where the FDA confirmed the proposed development pathway. The company said E&L data were required for the chemistry, manufacturing and controls (CMC) section of its planned new drug application (NDA). With extractables results meeting regulatory requirements, the company progresses to the leachables phase for comprehensive regulatory submission data. Watch: LTR's new appointment Progress on SPONTAN and new US-targeted ROXUS LTR Pharma continues to progress SPONTAN through established regulatory pathways while building commercial foundations through its Australian early access programs. It is also progressing its new ED nasal spray called ROXUS, which offers a fast-track pathway to serve patients through the US personalised healthcare sector. As with SPONTAN, ROXUS is based on the common active ingredient vardenafil. It will be delivered via the 503(a)-compounding pharmacy pathway, which exempts drugs from the usual approval, labelling and manufacturing requirements. "The completion of our extractables study and commencement of the leachables phase keep our regulatory program on schedule,' LTR Pharma executive chairman Lee Rodne said. 'Working with Aptar Pharma provides us with their established expertise in nasal spray device development and FDA submissions. 'These studies are necessary steps in our development pathway, and we look forward to progressing through each regulatory milestone." This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as LTR Pharma completes study milestone for SPONTAN ED treatment

Why fitness bros are embracing the ‘big butt' trend
Why fitness bros are embracing the ‘big butt' trend

News.com.au

time3 days ago

  • News.com.au

Why fitness bros are embracing the ‘big butt' trend

We've all heard the joke – that 'glute days' were something straight men skipped, and even mocked. The focus was always on having big arms or a six-pack, because that's what women liked. But now, straight men around the world are no longer neglecting their backsides and are focusing on exercises to give them a 'shelf-like butt'. Fitness bros are now fighting to use the hip thrust machine and swapping chest presses for dead lifts. Meanwhile, thousands of men are flocking to pilates classes, which is only adding to the idea that they're more focused on their glutes than ever. And the fact that over 400 men in the U.S. had Brazilian butt lifts last year backs this up – pun intended. Even brands are embracing the trend, launching male butt-enhancing leggings, underwear, and chinos. 'It was once laughed at,' said fitness coach John Rusin to GQ. 'And now people are standing in line at commercial centres to use the hip thrust machine.' Social media feeds reflect this change, with male fitness influencers talking directly to their followers about how to grow their glutes. But why has this shift occurred, and what are the potential fitness benefits? Reason behind the shift Like with most fitness trends, there's no one single reason for the change. Some fitness buffs simply want to look good from all angles. For others, it's about how stronger glute muscles help power other exercises, from lifting to running. For some, like Sydney-based gym-goer Jake, 35, growing his glutes was all about helping his lower back issues. 'I knew that I needed to grow my glutes to strengthen my lower back area,' he told 'The bigger glutes I gained from my rehab exercises were never a priority, but a nice bonus.' Rusin says this isn't an uncommon story. Strong glutes are known to help you move better: protect the knees; support the hips; and reduce lower back pain. 'Whether you're a man or woman, you can't afford not to train them,' he explained. Another reason for the shift is that male aesthetic trends often follow queer trends, and gay men have long appreciated a good butt. And the GQ writer suggests that female preferences are changing too, with 81 per cent of women who date men saying they 'love a good man butt'. Gyms are catching onto this shift, with companies like F45 now adding more glute-focused training to their workouts. 'We're adding more unilateral movements like single-leg RDLs and split squats, as well as sled pushes and hip-dominant step-ups. This is becoming more popular,' a spokesperson for F45 told the outlet. Tide is turning Jake says he's embracing the trend and will keep prioritising lower-body training. But he notes there has long been a stigma around these types of exercises for guys in his fitness community. 'I think focusing on glutes specifically has always come with a bit of a giggle,' he said. 'There's this idea that no one wants to be thought of as the guy who wants a good booty. But if you're skipping leg day, you're missing out – and you'll be the guy on the beach in summer too afraid to wear budgie smugglers. 'Drop the ego and drop your third upper body day of the week.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store